BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 17123400)

  • 1. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.
    Komvilaisak P; Connolly B; Naqvi A; Blanchette V
    Haemophilia; 2006 Dec; 12 Suppl 6():87-93. PubMed ID: 17123400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
    Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V
    Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus recommendations for use of central venous access devices in haemophilia.
    Ewenstein BM; Valentino LA; Journeycake JM; Tarantino MD; Shapiro AD; Blanchette VS; Hoots WK; Buchanan GR; Manco-Johnson MJ; Rivard GE; Miller KL; Geraghty S; Maahs JA; Stuart R; Dunham T; Navickis RJ
    Haemophilia; 2004 Sep; 10(5):629-48. PubMed ID: 15357790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous access in haemophilic children: choice and management.
    Santagostino E; Mancuso ME
    Haemophilia; 2010 Jan; 16 Suppl 1():20-4. PubMed ID: 20059565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia.
    Jeng MR; O'Brien M; Wong W; Zoland J; Lea J; Tang N; Glader B
    Haemophilia; 2009 Nov; 15(6):1272-80. PubMed ID: 19601989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI after removal of central venous access device reveals a high number of asymptomatic thromboses in children with haemophilia.
    Ranta S; Kalajoki-Helmiö T; Pouttu J; Mäkipernaa A
    Haemophilia; 2012 Jul; 18(4):521-6. PubMed ID: 22176603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central venous access device-related infections in patients with haemophilia.
    Yeoh ZH; Furmedge J; Ekert J; Crameri J; Curtis N; Barnes C
    J Paediatr Child Health; 2013 Mar; 49(3):242-5. PubMed ID: 23438133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central venous access devices in children with hemophilia: an update.
    Blanchette VS; Al-Musa A; Stain AM; Ingram J; Fille RM
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S11-4. PubMed ID: 9351530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of central venous catheters in haemophilia patients.
    Izzi G; Franchini M; Bonetti L; Tagliaferri A
    Haemophilia; 2010 Jan; 16 Suppl 1():29-31. PubMed ID: 20059567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters.
    Mancuso ME; Mannucci PM; Sartori A; Agliardi A; Santagostino E
    Br J Haematol; 2008 May; 141(5):689-95. PubMed ID: 18410458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central venous access device infections in children with hemophilia: a comparison of prophylaxis and episodic therapy.
    Hacker MR; Page JH; Shapiro AD; Rich-Edwards JW; Manco-Johnson MJ
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):458-64. PubMed ID: 17609623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central venous access devices in patients with hemophilia.
    Valentino LA; Kapoor M
    Expert Rev Med Devices; 2005 Nov; 2(6):699-711. PubMed ID: 16293097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethanol lock therapy for the treatment of catheter-related infections in haemophilia patients.
    Rajpurkar M; Boldt-Macdonald K; McLenon R; Callaghan MU; Chitlur M; Lusher JM; Becker C
    Haemophilia; 2009 Nov; 15(6):1267-71. PubMed ID: 19659937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS).
    Langley AR; Stain AM; Chan A; McLimont M; Chait S; Wu J; Poon MC; Card R; Israels SJ; Laferriere N; Klaassen RJ; Rivard GE; Cloutier S; Hawes S; Feldman B; Blanchette V
    Haemophilia; 2015 Jul; 21(4):469-76. PubMed ID: 26104147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous access in the management of hemophilia.
    Valentino LA; Kawji M; Grygotis M
    Blood Rev; 2011 Jan; 25(1):11-5. PubMed ID: 21030121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central venous access catheters in children with haemophilia.
    Blanchette VS; al-Musa A; Stain AM; Filler RM; Ingram J
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S39-44. PubMed ID: 8735796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk associated with indwelling catheters in children with haemophilia.
    Ljung R
    Br J Haematol; 2007 Sep; 138(5):580-6. PubMed ID: 17686052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study.
    Rodriguez V; Mancuso ME; Warad D; Hay CR; DiMichele DM; Valentino L; Kenet G; Kulkarni R
    Haemophilia; 2015 Sep; 21(5):e369-74. PubMed ID: 26178581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiologic placement of a low profile implantable venous access port in a pediatric population.
    Nosher JL; Bodner LJ; Ettinger LJ; Siegel RL; Gribbin C; Asch J; Drachtman RA
    Cardiovasc Intervent Radiol; 2001; 24(6):395-9. PubMed ID: 11907746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.